Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes

Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that is associated with severe functional impairment and a poor prognosis. Ambrisentan is a selective endothelin type A receptor antagonist approved for the treatment of patients with PAH World Health Organiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Elshaboury, Soha M, Anderson, Joe R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652514/
https://www.ncbi.nlm.nih.gov/pubmed/23674888
http://dx.doi.org/10.2147/PPA.S30949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652514/
https://www.ncbi.nlm.nih.gov/pubmed/23674888
http://dx.doi.org/10.2147/PPA.S30949

Ejemplares similares